A

    Avalo Therapeutics Inc (AVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.34
    -0.25 (-1.28%)

    Market Cap: $1.05B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    -364.81%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.50
    Range$-0.66 - $-0.22
    9 analysts
    EPS Revisions
    3
    0
    7d
    3
    2
    30d
    EPS Estimate Drift
    90d ago$-0.71-42.7%
    60d ago$-0.56-12.3%
    30d ago$-0.55-10.0%
    7d ago$-0.55-10.0%
    Current$-0.50
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Dec 31, 2026
    EPS Consensus$-0.42
    Range$-0.93 - $0.29
    9 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.42---
    Sep 26EST
    		-$-0.50---
    Jun 26
    		$-0.83$-0.66-25.76%Miss+56.8%
    Mar 26
    		$-0.98$-1.03+4.85%Beat+21.6%
    Dec 25
    		$-0.37N/A+75.25%Beat+86.5%
    Sep 25
    		$-2.19$-1.64-33.54%Miss-323.5%
    Jun 25
    		$-1.92$-1.43-34.27%Miss-145.6%
    Mar 25
    		$-1.25$-1.60+21.88%Beat+99.1%
    Dec 24
    		$-2.74$1.67-264.56%Miss+97.6%
    Sep 24
    		$0.98$-1.19+182.35%Beat+103.7%
    Jun 24
    		$4.21$-6.70+162.84%Beat+103.0%
    Mar 24
    		$-141.00$-1.18-11849.15%Miss-16488.2%
    Dec 23
    		$-116.21$-4.80-2321.04%Miss+53.4%
    Sep 23
    		$-26.40N/A+90.00%Beat-132.4%
    Jun 23
    		$-141.60$-168.00+15.71%Beat+57.2%
    Mar 23
    		$-0.85$-0.97+12.37%Beat+64.6%
    Dec 22
    		$-249.60$-156.00-60.00%Miss+45.8%
    Sep 22
    		$81.60N/A+125.89%Beat+116.7%
    Jun 22
    		$-331.20$-424.80+22.03%Beat+36.1%
    Mar 22
    		$-2.40$-1.60-50.00%Miss+37.5%
    Dec 21
    		$-460.80$-439.20-4.92%Miss+5.9%
    Sep 21
    		$-489.60$-518.40+5.56%Beat-6.3%
    Jun 21
    		$-518.40$-508.80-1.89%Miss-9.6%
    Mar 21
    		$-3.84$-2.32-65.52%Miss+98.4%
    Dec 20
    		$-489.60$-432.00-13.33%Miss-136100.0%
    Sep 20
    		$-460.80$-273.60-68.42%Miss-116.1%
    Jun 20
    		$-472.89$-302.40-56.38%Miss-61.6%
    Mar 20
    		$-247.39$-355.20+30.35%Beat+31.8%
    Dec 19
    		$0.36N/A-57.14%Miss+116.7%
    Sep 19
    		$-213.23$-388.80+45.16%Beat+89.6%
    Jun 19
    		$-292.61$-470.40+37.80%Beat+46.5%
    Mar 19
    		$-362.88$-470.40+22.86%Beat-14.5%
    Dec 18
    		$-2.16$-0.60-260.00%Miss-100.1%
    Sep 18
    		$-2044.78$-345.60-491.66%Miss-407.1%
    Jun 18
    		$-547.20$-288.00-90.00%Miss-23900.0%
    Mar 18
    		$-316.80N/A+52.17%Beat+42.4%
    Sep 17
    		$1497.59$-374.40+500.00%Beat+175.0%
    Jun 17
    		$-403.20$-633.60+36.36%Beat-
    Mar 17
    		$-2.28$-4.44+48.65%Beat-
    Dec 16
    		$-549.85N/A+69.21%Beat-
    Sep 16
    		$-1995.77$-1411.19-41.42%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.43EV/EBITDA-0.19x
    Price/FCF-12.35xFCF Yield-8.10%
    Profitability
    Profit Margin0.00%Operating Margin-154847.00%
    ROE-36.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio19.31xQuick Ratio19.31x
    Trading Statistics
    Beta0.79Avg Volume746.99K
    52-Week High$24.2752-Week Low$8.65

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$19.86
    SMA 20$19.54
    SMA 50$19.00
    SMA 200$16.85
    EMA 10$19.72
    EMA 20$19.53
    EMA 50$18.74
    EMA 200$16.24

    MACD

    Line: 0.32Signal: 0.39Hist: -0.08

    ADX

    ADX: 18.8+DI: 21.0-DI: 19.8

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down24.0
    PSAR$19.00

    Bollinger Bands

    Upper Band$20.76
    Lower Band$18.32
    %B Position1245%(Upper)
    Band Width0.42

    RSI (14-Day)

    Neutral
    49.9

    Momentum Oscillators

    Stoch %K50.6
    Stoch %D62.6
    Williams %R-62.7
    ROC (10d)-3.1%
    Momentum-0.61
    CCI (20d)-25.7
    MFI (14d)48.2

    Volatility Measures

    ATR (14d)$1.00(5.2%)
    StdDev (20d)0.61
    Hist Vol48.0%(High)

    Volume Flow

    VWAP$19.32
    OBV30.7M
    AD Line-5.1M
    CMF (20d)0.058

    Volume Metrics

    Avg Vol (20d)755.7K
    Vol Ratio1.8x(High)
    VWMA (20d)$19.53

    Pivot Points

    R3$20.63
    R2$20.40
    R1$20.00
    Pivot Point$19.77
    S1$19.36
    S2$19.13
    S3$18.73

    Advanced Oscillators

    TSI8.73
    Ultimate Osc49.0
    KST53.90

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$59,000$0$0$0$192,000$249,000$0$0$570,000$236,000
    Cost of Revenue$0$0$16,000$0$0$0$85,000$-714,000$343,000$-80,000$-222,000$247,000
    Gross Profit$0$0$59,000$0$0$0$107,000$963,000$-343,000$80,000$792,000$-11,000
    Operating Expenses$31.52M$20.90M$19.80M$19.20M$19.32M$14.67M$13.42M$13.82M$9.23M$32.85M$8.45M$3.74M
    R&D$23.42M$14.05M$13.27M$13.62M$14.07M$9.12M$8.18M$9.54M$4.70M$29.65M$1.87M$1.25M
    SG&A$8.10M$6.85M$6.54M$5.58M$5.24M$5.55M$5.23M$4.29M$4.53M$3.19M$2.67M$2.49M
    Operating Income$-31,517,000$-20,901,000$-19,742,000$-19,198,000$-19,316,000$-14,669,000$-13,309,000$-12,861,000$-9,575,000$-32,767,000$-7,659,000$-3,750,000
    Interest Income$2.76M$803,000$984,000$1.12M$1.10M$1.15M$1.21M$964,000$1.04M$100,000$81,000$-1,553,000
    Interest Expense$4.82M$0$0$11.42M$1.43M$0$21.92M$0$0$88.52M$518,000$1.47M
    Income Before Tax$-36,340,000$-19,618,000$-13,590,000$-30,614,000$-20,749,000$-13,141,000$-35,225,000$23.02M$98.47M$-121,283,000$-8,177,000$-5,220,000
    Income Tax Expense$18,000$12,000$130,000$11,000$16,000$8,000$114,000$-14,000$7,000$7,000$-9,000$8,000
    Net Income$-36,358,000$-19,630,000$-13,720,000$-30,625,000$-20,765,000$-13,149,000$-35,339,000$23.04M$98.46M$-121,290,000$-8,168,000$-5,228,000
    EBITDA$-39,502,000$-20,510,000$-14,755,000$-32,019,000$-21,858,000$-14,154,000$-36,366,000$22.09M$97.46M$-121,349,000$-8,215,000$-2,497,000
    EBIT$-39,101,000$-20,421,000$-14,574,000$-31,731,000$-21,846,000$-14,289,000$-36,434,000$22.06M$97.43M$-121,383,000$-8,258,000$-3,667,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AVTX

    News

    Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares

    Mittie Doyle, Chief Medical Officer at Avalo Therapeutics, sold 1,000 shares of company stock worth $20,000 on August 17, 2026, as part of a pre-arranged trading plan, while also exercising options for 1,000 shares. These transactions occurred amidst significant company developments, including its inclusion in the Russell 2000 and 3000 indexes and positive analyst ratings. The stock has seen a 108% return over the past year.

    Investing.com•8/26/26•
    Neutral

    Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com

    Avalo Therapeutics' CFO, Christopher Ryan Sullivan, sold over $1.45 million in company stock on August 17 and 18, 2026, under a Rule 10b5-1 trading plan. The sales occurred after he exercised stock options, with the company's shares having seen a 110% return over the past year. Despite the sales, Avalo Therapeutics has recently seen positive developments including new analyst coverage, inclusion in Russell indexes, and a new board appointment.

    Investing.com Canada•8/25/26•
    Somewhat-Bearish

    Avalo Therapeutics CFO sells over $1.45 million in stock

    Christopher Ryan Sullivan, CFO of Avalo Therapeutics (NASDAQ:AVTX), sold over $1.45 million in company stock and exercised options on August 17 and 18, 2026, under a Rule 10b5-1 trading plan. These transactions occurred as AVTX shares saw a 110% return over the past year. The company has also recently received positive analyst coverage, been added to the Russell indexes, and appointed a new board member.

    Investing.com•8/25/26•
    Somewhat-Bearish

    Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX

    Avalo Therapeutics, Inc. (NASDAQ: AVTX) generated $59,000 USD in revenue last year, primarily from its Pharmaceutical segment. This marks a significant decrease compared to the $441,000 USD earned in the previous year. The United States was the sole contributor to this revenue.

    TradingView•8/22/26•
    Neutral

    Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan

    Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, exercised options to acquire 1,000 shares of common stock at $12.65 per share and subsequently sold those 1,000 shares at $20.00 per share. These transactions, which occurred on August 17, 2026, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following these transactions, Doyle directly holds 123,750 shares of common stock.

    Stock Titan•8/20/26•
    Neutral

    Frequently Asked Questions About AVTX

    Does AVTX pay dividends?
    Avalo Therapeutics Inc (AVTX) does not currently pay a regular dividend.
    What is AVTX's market cap?
    Avalo Therapeutics Inc (AVTX) has a market capitalization of $1.05B with a current stock price of $19.34.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In